In today's (2020) news of the pharmaceutical industry, in addition to the research and development of vaccines and drugs in novel coronavirus, the recent merger of American manufacturer AbbVie and Irish manufacturer Allergan is also the focus of attention. Because the amount of this merger is as high as $63 billion, and AbbVie owns biopharmaceuticals that have won the global drug sales champion for more than ten years in a row, Allergan owns many products with the first brand of medical beauty, including the well-known Botox injection.
Abbey ranks first in the fields of Great Leap Forward immunization, hepatitis C and medical beauty.
The combined AbbVie has more than 30 products, covering more than 60 diseases. In immunology, hepatitis C and medical beauty, it ranks first in the world and second in blood tumors. Ophthalmology and women's medical care are in the leading position. Due to the expansion of scale, AbbVie jumped from the ninth largest pharmaceutical factory in the world to the fourth. In Taiwan Province province, it rose from 13 to the former 10.
Abbey used to be the western medicine department of Apex. It was separated from Apex seven and a half years ago, and its performance has attracted much attention. It was recognized by the National Biotechnology Medical Quality Award "Three Gold and Two Silver", which is known as the "Oscar in Biotechnology Medical Field" in China, and actively demonstrated its innovative drug research and development strength and ambition. Actively promote the listing and clinical trials of new drugs in Taiwan Province. At present, there are more than 60 clinical trials in many medical centers in Taiwan Province. The company was also awarded the Best Employer Award at home and abroad.
Ailigen, the leader in the field of medical beauty, merged two major pharmaceutical companies to strive for diversified outlets.
The global output of Allergan's classic ace drug Botox Injection exceeds 1 100 million bottles (20 19). In addition to being a leader in medical beauty, she has been approved 1 1 indications in the professional medical field, covering chronic migraine, spasm, torticollis and overactive bladder.
Allegan has world-class medical aesthetics and drugs for ophthalmology, gastrointestinal diseases and central nervous system treatment. AbbVie has strong R&D and commercial capabilities, and has international influence in 175 countries. The merger has found a way out for both parties and eased the challenge of relying too much on the best-selling drugs of a single star. Moreover, there are many new product groups developed by the two companies, and all walks of life are paying close attention to the future trends.
Wei, general manager of Taiwan Province Branch of AbbVie Pharmaceutical, pointed out that the merged new AbbVie focuses on immunology, oncology, virology, ophthalmology, neurology, medical beauty, gastroenterology, women's health and other special fields.
After the merger, Abbevie was in charge of the treatment field, and the ophthalmology medical and neuroscience team originally belonging to Allegan was merged into Abbevie. Allegan Medical Beauty operates independently. Wei further explained that because the brand name of "Alegen" is deeply rooted in the hearts of consumers/patients and medical staff in the field of medical beauty and ophthalmology, ophthalmology and medical beauty continue to retain the name of "Alegen" in marketing.
Lin, general manager of Allegheny Medical Beauty Desk in Hong Kong and Macao, said that Allegheny's various medical beauty products are world-renowned. We will continue to develop new therapies and equipment, focus on caring skin condition, eliminating fat, solving facial lines and filling problems, continue to provide differentiated services to customers, and strengthen our leading position in the field of medical beauty.
Join us and pay attention to your health every day! Ok @ ID: @ Subscribe to the healthy Aloha audio-visual channel to read health knowledge more easily:/supply/article/45171Keywords: Wei, Lin, Abby, Allergan, medical beauty, ophthalmology.